GeneDx Holdings Corp. (WGS) News
Track canonical SquawkNews coverage tagged to WGS, GeneDx Holdings Corp.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
GeneDx and Beren Therapeutics launch NPC GenomeComplete testing program
GeneDx announced a collaboration with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete Sponsored Testing Program, offering no-cost comprehensive genome sequencing for eligible Niemann-Pick disease type C patien
EQUITY | Sep 09, 2026, 12:30 PM UTC
M
WGS Q2 volumes rise 32% on new markets and automation
WGS said Q2 volumes grew 32%, attributing momentum to core channels and expansion into primary care and prenatal markets underway. Management cited untapped potential in geneticists, pediatric neurology and NICU, plus co
EQUITY | Sep 08, 2026, 07:45 PM UTC
L
WGS reports Q2 volume growth of 32%
WGS said Q2 volume grew 32%, with initiatives underway to expand and improve margins. Management cited core-market strength while targeting additional potential in geneticists, pediatric neurology and NICU.
EQUITY | Sep 08, 2026, 07:08 PM UTC
L
GeneDx publishes study on rapid genome sequencing in pediatric care
GeneDx says a study published in Genetics in Medicine shows hospital-wide first-tier rapid genome sequencing improved diagnostic rates, reduced time to diagnosis, and enhanced operational efficiency in pediatric inpatien
EQUITY | Aug 24, 2026, 12:34 PM UTC
L
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M Est
GeneDx Holdings (NASDAQ: WGS ) affirms FY2026 sales outlook from $475.000 million-$490.000 million to $475.000 million-$490.000 million vs $478.367 million estimate.
EARNINGS | Aug 03, 2026, 08:19 PM UTC
L
WGS - GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
WGS - GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
EQUITY | Jul 31, 2026, 08:08 AM UTC
L
WGS WGS - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS - Click For R
WGS WGS - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
REGULATION | Jul 30, 2026, 02:08 PM UTC
L
WGS - HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud
WGS - HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
EQUITY | Jul 28, 2026, 02:10 PM UTC
L
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, July 06, 2026 (GLOBE NEWSWIRE) -
EQUITY | Jul 06, 2026, 02:14 PM UTC
L
WGS INVESTORS: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to L
SAN DIEGO, July 05, 2026 (GLOBE NEWSWIRE) -
EQUITY | Jul 05, 2026, 04:50 PM UTC
L
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) -- Hagens Berman (HBSS), a national leader in securities li
EQUITY | Jul 03, 2026, 06:21 PM UTC
L
GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Ch
Did you buy WGS securities between April 16, 2025, and May 4, 2026
EQUITY | Jul 03, 2026, 05:05 PM UTC
L
WGS LAWSUIT ALERT: Levi & Korsinsky Notifies GeneDx Holdings Corp. Investors - Lead Plaintiff Deadline August 3, 2026
NEW YORK, NY / / July 3, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise
EQUITY | Jul 03, 2026, 04:55 PM UTC
M
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74
Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ: WGS ) with a Buy and raises the price target from $70 to $74.
EQUITY | Jun 29, 2026, 02:07 PM UTC
M
WGS: Piper Sandler Raises Target
Piper Sandler maintains overweight rating on GeneDx Holdings and raises price target to $63
EQUITY | Jun 23, 2026, 04:42 PM UTC